MAX-10181 in Patients With Advanced Solid Tumor

Solid Tumor Clinical Trial

— PD-L1  

Official title:

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of MAX-10181 in Patients With Advanced Solid Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05196360
• Other study ID #: MAX-10181-002
• Secondary ID: MAX-10181
• Status: Recruiting
• Phase: Phase 1
• Start date: August 11, 2021
• Est. completion date: May 1, 2023

Study information

• Verified date: January 2022
• Source: Maxinovel Pty., Ltd.
• Contact: Hanying bao, MD,Ph.D
• Phone: +86-021-51370693
• Email: hybao[@]maixnovel.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

Description:

This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: May 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and/or females over age 18.
• Histologically or cytologically confirmed advanced or metastatic solid tumor for -which no established standard therapy is available.
• At least one measurable lesion by CT or MRI according to RECIST1.1, which is not in irradiated area (only for expansion phase).
• Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (in case of alopecia, Grade 2 is acceptable).
• Life expectancy of at least 3 months.
• Female participants of child bearing potential agree not to be pregnant or lactating during the study and for three months following the last dose of study drug. Both men and women of reproductive potential must agree to use a highly effective method of birth control during the study and for three months following the last dose of study drug. A highly effective method of contraception is defined as one that results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly.

Exclusion Criteria:

• Laboratory values not within the Protocol-defined range.
• Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
• Previously treated malignancies other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry.
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery.
• Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
• Anti-cancer treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), hormone therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry.
• Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
• History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis.
• History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation.
• Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• MAX-10181
Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria. Part 2: Dose expansion, Recommended doses from Part 1.

Locations

Country	Name	City	State
China	The First Affiliated Hospital, Zhejiang University	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Maxinovel Pty., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events (AEs)	Incidence of treatment-related AEs	3 years
Primary	Maximum tolerated dose (MTD)	MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing.	4 weeks
Primary	Phase II dose (RP2D)	The number and proportion of patients experiencing at least 1 dose-limiting toxicity (DLT) will be used as the primary measure to evaluate the RP2D of MAX-10181.	4 weeks
Secondary	Tmax	Time to maximum plasma concentration	Approximately 4 weeks
Secondary	Cmax	Time to maximum plasma concentration; [Time Frame: Approximately 4 weeks]	Approximately 4 weeks
Secondary	AUC	Area under the time-concentration curve	Approximately 4 weeks
Secondary	t1/2	Observed terminal half-life	Approximately 4 weeks
Secondary	Objective response rate (ORR)	The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.	12 months (anticipated)